Phase II Study of Volrustomig with Chemotherapy for Treatment of Non-small Cell Lung Cancer

What this Trial Is About

Researchers are studying volrustomig combined with other anticancer drugs to assess its safety, tolerability, how the body processes it, immune response, and ability to fight solid tumors, focusing on various types of metastatic non-small cell lung cancer mNSCLC. This Phase II open-label study includes two substudies, with participants randomized into different treatment arms based on tumor types and treatment regimens. Participants will receive volrustomig by intravenous infusion combined with chemotherapy drugs such as carboplatin, pemetrexed, ramucirumab, or paclitaxel, depending on the assigned treatment arm. The study tests different volrustomig dosing regimens alongside these anticancer agents to explore their combined effects in mNSCLC. Two substudies focus on non-squamous and squamousnon-squamous mNSCLC with specific treatment combinations. During the trial, participants will undergo regular monitoring for adverse events and treatment responses for up to nearly three years. Researchers will evaluate tumor response rates, disease control, survival, and drug levels in the blood. Safety and immune responses will also be tracked throughout. Participants can expect scheduled visits for infusions, assessments, and tests to measure the study treatments effects and safety over the study period.

Volrustomig Priming Regimens Exploratory Phase II Platform Study